share_log

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apollomics | 6-K:外國發行人報告
美股sec公告 ·  05/09 04:11
牛牛AI助理已提取核心訊息
On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.
On May 6, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the entry into PIPE Subscription Agreements with certain accredited investors, with the closing expected on May 8, 2024. The company will issue 19,166,666 Class A ordinary shares at $0.30 each, aiming to raise $5.75 million before fees and expenses. The funds are intended for pipeline programs, general corporate purposes, and working capital. Additionally, Apollomics appointed Dr. Bob Lin to its board of directors and announced the resignation of Dr. Jonathan Wang from the board for personal reasons. The company emphasized that Dr. Wang's departure was not due to any disagreements with company operations or practices. Apollomics plans to file a registration statement with the SEC for the resale of the PIPE shares within thirty days post-closing. The securities offered in the PIPE are not registered under the Securities Act of 1933 and are subject to customary closing conditions.
2024年5月6日,處於臨床階段的生物製藥公司Apollomics Inc. 宣佈與某些合格投資者簽訂PIPE認購協議,預計將於2024年5月8日結束。該公司將以每股0.30澳元的價格發行19,1666股A類普通股,目標是在扣除費用和支出前籌集575萬澳元。這些資金用於管道計劃、一般公司用途和營運資金。此外,Apollomics任命鮑勃·林博士爲董事會成員,並宣佈王喬納森博士因個人原因辭去董事會職務。該公司強調,王博士的離職不是由於與公司運營或實踐有任何分歧。Apollomics計劃在收盤後三十天內向美國證券交易委員會提交一份關於轉售PIPE股票的註冊聲明。PIPE提供的證券未根據1933年《證券法》註冊,並受慣例成交條件的約束。
2024年5月6日,處於臨床階段的生物製藥公司Apollomics Inc. 宣佈與某些合格投資者簽訂PIPE認購協議,預計將於2024年5月8日結束。該公司將以每股0.30澳元的價格發行19,1666股A類普通股,目標是在扣除費用和支出前籌集575萬澳元。這些資金用於管道計劃、一般公司用途和營運資金。此外,Apollomics任命鮑勃·林博士爲董事會成員,並宣佈王喬納森博士因個人原因辭去董事會職務。該公司強調,王博士的離職不是由於與公司運營或實踐有任何分歧。Apollomics計劃在收盤後三十天內向美國證券交易委員會提交一份關於轉售PIPE股票的註冊聲明。PIPE提供的證券未根據1933年《證券法》註冊,並受慣例成交條件的約束。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。